Skip to content

The 5 Clinical Trial Performance Metrics Every Site Should Track for Business Development

Clinical Trial Performance Metrics

Webinar Date: December 6, 2019

Webinar Guest: Sean Rice

Track your clinical trial performance metrics to take control of your pipeline. Investing in the long haul means having robust business development capabilities now. That starts with data. Join Sean Rice, CEO of Medical Research Alliance and Co-Founder of Devana Solutions as he discusses the 5 metrics every site should track when working with sponsors. Sean explains each metric in depth, the rationale behind it, and potential pitfalls.

Check out CRIO’s Custom Reporting module within our CTMS to ensure in-depth analytics across your site.

by Megan Richards Customer Experience Manager at CRIO
Share this post
You may also find interesting
Explore our Blog
Progress notes are vital to source data Running a Study

Progress Notes are Vital to Source Data

Progress notes are free-text entries by the investigator, coordinator or study team member that are inserted into the source record. Generally, these play a critical and highly undervalued role in the study process. Progress notes are often used to: Clarify or confirm any data points that may appear as outliers, even before a query is...

Hand of businessman using smart phone with coin icon, technology, clinical trials operations Running a Study

Sponsors, Funding is Tight – Be Smart with Your Money

Getting a new product to market is expensive. There are a variety of studies and research that point to a wide array of costs, but generally speaking, it costs nearly $3 billion dollars to bring a new drug to market. Yes, you read that correctly. Beyond this, the success rate of a new compound to...

DCT Draft Guidance explained Running a Study

The FDA’s Decentralized Clinical Trials Draft Guidance Explained

The highly anticipated Decentralized Clinical Trials (DCT) draft guidance from the FDA was finally released on 02-May-2023. In this 19-page document, the FDA outlines its current thinking around the concept of DCTs. From the outset of the draft guidance, the FDA makes a clear point on what DCTs can mean for patients and the patient...